GENTA SHARES FALL ON FDA SUMMARY

Shares of drug developer Genta Inc. dropped sharply Tuesday after the Food and Drug Administration questioned whether its leukemia treatment candidate would offer any substantial improvement over chemotherapy.
Houston Chronicle